Loading company
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Nasdaq · ·
Next earnings: November 11, 2026
$6.60-4.6%Sep 29 close
- 1M
- -39.5%
- 6M
- -23.3%
- 1Y
- -47.8%
- 5Y
- -79.6%
CRBP · Nasdaq · ·
Next earnings: November 11, 2026
$6.60-4.6%Sep 29 close
Corbus Pharmaceuticals Holdings, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toSep 30, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $97.3K | -100.00% |
| Profit | -$35M | -$17.7M | -98.38% |
| Profit per share | -$1.81 | -$1.44 | -25.69% |
| Free Cash Flow | -$29.6M | -$6M | -393.21% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We’ve continued to build momentum as we prepare for two potentially impactful clinical development milestones in September: commencing enrollment of TEMPO-1, our Phase 3 study of CRB-701 in oropharyngeal cancer, and the data readout of CANYON-1, our Phase 1b study of CRB-913 in obesity. Both programs represent opportunities to address areas of significant unmet medical need,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Corbus Pharmaceuticals Holdings, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Corbus Pharmaceuticals Holdings, Inc. has no earnings call transcript available.